Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 0.37 |
| ▸ | CALML3 | P27482 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
| ▸ | FADS1 | O60427 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038586 | 0.79 | MAOA (0.45) | MAOACALML3MAOB | |
| SCHEMBL3043443 | 0.75 | MAOA (0.43) | MAOAMAOBFADS1 | |
| SCHEMBL3043447 | 0.74 | MAOA (0.47) | MAOACALML3MAOB | |
| SCHEMBL3043513 | 0.73 | FADS1 (0.36) | CALML3FADS1 | |
| SCHEMBL6365509 | 0.73 | CALML3 (0.61) | MAOACALML3MAOB | |
| SCHEMBL5232769 | 0.73 | CALML3 (0.61) | MAOACALML3MAOB | |
| SCHEMBL1176420 | 0.72 | MAOA (0.71) | MAOACALML3MAOB | |
| SCHEMBL1176417 | 0.72 | MAOA (0.71) | MAOACALML3MAOB | |
| SCHEMBL3043319 | 0.71 | MAOA (0.40) | MAOAMAOBFADS1 | |
| SCHEMBL6403061 | 0.68 | MAOA (0.47) | MAOACALML3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885CALML3 3149/4885MAOB 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.